$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019
[Lowest Price Guaranteed: $2,000]

Published by Global Markets Direct: 30 Aug 2019 | 236530 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape.

Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Elephantiasis (Lymphatic Filariasis) - Overview

    Elephantiasis (Lymphatic Filariasis) - Therapeutics Development

    Pipeline Overview

    Pipeline by Companies

    Pipeline by Universities/Institutes

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment

    Assessment by Route of Administration

    Assessment by Molecule Type

    Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development

    AbbVie Inc

    Eisai Co Ltd

    Medicines Development Ltd

    Elephantiasis (Lymphatic Filariasis) - Drug Profiles

    ABBV-4083 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AWZ-1066S - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    EDE-1206 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    filariasis vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lymphatic filariasis (multivalent) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    lymphatic filariasis (multivalent) vaccine - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    moxidectin - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Elephantiasis (Lymphatic Filariasis) - Dormant Projects

    Elephantiasis (Lymphatic Filariasis) - Product Development Milestones

    Featured News & Press Releases

    Jan 08, 2019: New anti-Wolbachia drug with potential to treat onchocerciasis and lymphatic filariasis

    Sep 14, 2018: £1.5M to develop candidate drug to treat onchocerciasis and lymphatic filariasis

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

236530 | GMDHC11376IDB

Number of Pages

30

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Elephantiasis- Market Insights, Epidemiology and Market Forecast 2028
Report Summary"Elephantiasis- Market Insights, Epidemiology and Market Forecast 2028" report provide...
26 Jul 2019 by MIReports USD $5,980 More Info
2019 Elephantiasis (Lymphatic Filariasis) Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Elephantiasis (Lymphatic Filariasis) Clinical Trials Study” ...
24 Apr 2019 by VPA Research USD $1,799 More Info
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2018SummaryGlobal Markets Direct's latest...
17 Jul 2018 by Global Markets Direct USD $2,000 More Info
Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2017
Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2017SummaryGlobalData's clin...
11 Aug 2017 by Global Data USD $2,500 More Info
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest...
18 Jul 2017 by Global Markets Direct USD $2,000 More Info
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2017
Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest...
28 Feb 2017 by Global Markets Direct USD $2,000 More Info
Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2015
Elephantiasis (Lymphatic Filariasis) Global Clinical Trials Review, H2, 2015SummaryGlobalData's clin...
30 Oct 2015 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...